Tvardi Therapeutics, Inc.
TVRD
$3.02
$0.020.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.24% | -23.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.77% | -33.05% | |||
| Operating Income | -27.77% | 33.05% | |||
| Income Before Tax | -31.63% | -232.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.63% | -232.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.63% | -232.64% | |||
| EBIT | -27.77% | 33.05% | |||
| EBITDA | -27.88% | 33.14% | |||
| EPS Basic | -31.57% | -216.64% | |||
| Normalized Basic EPS | -31.57% | -216.66% | |||
| EPS Diluted | -31.44% | 41.25% | |||
| Normalized Diluted EPS | -31.57% | -219.61% | |||
| Average Basic Shares Outstanding | 0.04% | 13.71% | |||
| Average Diluted Shares Outstanding | 0.04% | 10.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||